GLENMARK PHARMACEUTICALS: Ichnos Glenmark Innovation's Trispecific TREAT™ Antibody, ISB 2001, Shows High Overall Response Rate in Heavily Pretreated Multiple Myeloma Patients

Ichnos Glenmark Innovation (IGl) presented first clinical data from the early dose-escalation portion of its Phase 1 study of ISB 2001 for the treatment of relapsed or refractory multiple myeloma (RRMM). The trispecific TREAT™ antibody targets BCMA and CD38 on myeloma cells and CD3 on T cells. The study showed an overall response rate (ORR) of 75% (15/20) across all doses tested, with a stringent complete remission (sCR) and complete remission (CR) rate of 20%. The ORR was 83% among the 18 patients treated at active doses, including sCR/CR rate of 22%. The safety profile was mild with good tolerability, comparing favorably with first-generation 1+1 bispecifics. The data suggest ISB 2001 could compare favorably with approved bispecific options.